HTSC·2026-03-19 02:55Investment Rating - The report maintains an "Overweight" rating for the biopharmaceutical and chemical pharmaceutical sectors [6]. Core Insights - The Chinese innovative drug sector is at the beginning of a long cycle, with continuous global output of high-quality assets from Chinese companies. The potential of these assets is not fully reflected in A/H share pricing, leading to a recommendation for the innovative drug sector [1]. - The number and value of business development (BD) deals in the Chinese innovative drug industry have reached record highs in 2023, with 45 BD deals completed (+73% year-on-year) and a total disclosed amount of $57.5 billion (+135% year-on-year) [2]. - The report highlights a significant valuation gap between A/H shares and US stocks for similar innovative drug assets, indicating that A/H shares are systematically undervalued [4]. Summary by Sections Business Development Trends - The report notes that the Chinese innovative drug sector has achieved a global market share of approximately 20% in the number of BD projects and around 75% in the disclosed amount [2]. - There is a high predictability of continued growth in BD activities, driven by increasing interest from multinational corporations (MNCs) and private equity (PE) firms in Chinese assets [2]. Cash Flow Contributions - The report emphasizes that platform companies in China are expected to generate sustainable cash flows through ongoing BD activities, which have not been adequately valued in the market [3]. - It is projected that significant BD deals (with upfront payments exceeding $500 million) will contribute to continuous cash flow growth for companies like Heng Rui Medicine, Shiyao Group, and others [3]. Valuation Comparisons - The report compares the valuations of similar assets in A/H shares and US markets, revealing that Chinese innovative drug companies are undervalued relative to their US counterparts [4][19]. - Specific case studies illustrate the valuation discrepancies, such as between MSD and Kelun Biotech, and Insmed and Haizhi Pharmaceutical, highlighting the potential for significant upside in A/H share valuations [19][22]. Investment Recommendations - The report recommends focusing on large pharmaceutical and biopharmaceutical companies with sustained BD capabilities, including Heng Rui Medicine, Shiyao Group, and others [5]. - Companies that have completed large BD deals are expected to benefit from ongoing milestone cash flows, with specific recommendations for companies like Kelun Biotech and Rongchang Biopharmaceutical [5]. Target Prices and Market Outlook - Target prices for recommended stocks are provided, with specific price targets for companies such as Shiyao Group at HKD 19.25 and Heng Rui Medicine at HKD 98.43, indicating a bullish outlook for these stocks [26].